4 Practical Neurology

review

Pract Neurol 2010; 10: 415

Neurolupus
Fady G Joseph,1 Neil J Scolding2
Systemic lupus erythematosus (SLE) is not an uncommon condition. Most neurologists are well aware that it can cause a wide range of neurological complications, and SLE almost invariably appears on differential diagnosis lists in cases of clinical uncertainty. However, the precise nature of the manifestations of SLE in the central and peripheral nervous systems is perhaps less widely understood, and misperceptions about phenomenology and treatment are common. Here we survey some of the main primary neurological complications of SLEneurolupuswhile acknowledging that secondary problems, either iatrogenic or relating to other consequences of SLE (eg, hypertensive CNS disease, for example, secondary to renal lupus) are neither less serious nor less treatable.

iNTrODUCTiON
Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations ranging from trivial and ephemeral to life threatening. Improved therapeutic options in recent years have enhanced survival rates in the face of a rising incidence over the past four decades (the last probably in part due to better recognition). The current estimated prevalence of SLE ranges from 6 to 150 per 100 000, and depends on sex and racial origin there is a 510 times higher risk in females, AfricanCaribbeans and Asians.1 The diagnosis is usually based on the American College of Rheumatology (ACR) criteria (table 1) which require at least four of the 11 listed features at some time in the course of the illness.2 Involvement of the nervous system cognitive and psychiatric, central and peripheral nervous, all inclusively referred to as neurolupus in this brief accountrepresents a much dreaded complication, and is common.3 Precisely how common has proved difficult if not impossible to establish. Published studies give figures ranging (remarkably) from 14% to over 90% of SLE patients developing neurological or psychiatric symptoms at

some time during their illness, the unhelpfully large range a result of studying fundamentally different populations and of substantial

TABLe 1 Diagnosis of systemic lupus erythematosus based on the American College of rheumatology criteria
Four out of the 11 features are required: Malar rash Discoid rash Photosensitivity (see figure 1) Oral ulcers Arthritis Serositis (pleurisy or pericarditis) Renal disorder (proteinuria >0.5 g/24 h or cellular casts) Neurological disorder Haematological disorder (haemolytic anaemia, leucopenia or lymphopenia on two or more occasions, or thrombocytopenia) Immunological disorder Antinuclear antibody

Consultant Neurologist, Neville Hall Hospital, Abergavenny and the Royal Gwent Hospital, Newport, UK Burden Professor of Clinical Neurosciences, Department of Neurology, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK Correspondence to Professor N Scolding, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK; n.j.scolding@bristol. ac.uk

10.1136/jnnp.2009.200071

Joseph, Scolding 5

differences in the definition and criteria used to designate nervous system involvement.46 Many authorities, possibly depending more on resigned guesswork than sound epidemiology, suggest 50% may be about right. Despite its gravity, however, SLE is potentially treatable, making it important for neurologists to be aware of the spectrum of neurolupus and its management.

PATHOLOGY AND PATHOGeNeSiS

In order to understand neurolupus and to rationalise investigations and treatment, it is useful to have a basic understanding of the underlying disease mechanisms.7 The principal neuropathological changes are those of infarction in the territory of small vessels, particularly in the cerebral cortex and brainstem (table 2). Vasculitis (true inflammatory infiltrate and destructive change within the blood vessel wall) is rare in neurolupus. There is extravasation of fibrin and red blood cells, together with endothelial cell proliferation, hypertrophy and the appearance of fibrin thrombi9 (figure 2). These non-inflammatory proliferative changes appear to be responsible for the numerous areas of microinfarction. Less commonly, macroscopic infarction or haemorrhage occurs, the former occasionally due to embolism from LibmanSacks endocarditis, or to the consequences of antiphospholipid antibodies (APAs). A common suggestion is that focal manifestations, including stroke, are predominantly

Figure 1 One of the features of lupus (see table 1). Credit: SPL.

TABLe 2 Neuropathology of systemic lupus erythematosus: a summary of four published papers

Johnson and richardson (1968)8 No of cases Vasculopathy (%) Vasculitis (%) Gross infarcts (%) Microinfarcts (%) Large haemorrhage (%) Microhaemorrhages (%) Infection (%) Heart: endocardial lesions/mural thrombi (%) ND, not determined.
www.practical-neurology.com

ellis and verity (1979)9 57 65 7 12 35 42 29 28 ND

Devinsky et al (1988)10 50 ND 0 22 ND 6 ND 16 50

Hanly et al (1992)11 10 ND 10 10 40 0 30 10 ND

24 83 13 25 71 21 25 0 33

6 Practical Neurology
Figure 2 (A, B) Cerebral microvascular thrombosis in the antiphospholipid syndrome, clinically and angiographically mimicking CNS vasculitis. Reprinted with permission from Lie and others (1997).50

caused by vascular occlusion, while diffuse manifestations, such as psychiatric features, may result from pathogenic antineuronal antibodies. Indeed, a hallmark of SLE is autoantibody production (table 3, figure 3). In principle, in neurolupus, antibodies could mediate neurological injury by reacting against neuronal, astroglial or endothelial cells.7 Changes could also be induced in the cerebral vasculature, either through immune complex deposition or effects on the coagulation system leading to infarction. These proposals are not mutually exclusive. In addition, well recognised abnormalities of cytokines, complement components, immune related

TABLe 3 The common and diagnostically helpful antibodies in neurolupus

Antinuclear antibodies (ANA) are the serological hallmark of systemic lupus erythematosus (SLE), present in the serum of virtually every patient at some time during the course of the disease. They may also be found in normal individuals where their prevalence increases with age; they are therefore sensitive but not specific for the disease: Anti-DNA antibodies include anti-single stranded (ssDNA) antibodies that target purine and pyrimidine bases of denatured DNA and anti-double stranded (dsDNA) antibodies that seek the ribose phosphate backbone of native DNA. Anti-dsDNA antibodies are reasonably specific for SLE but are only present in about 70% of patients; they can be used to monitor disease activity. They may contribute to disease pathology7 but are sometimes found in normal individuals and those with rheumatoid arthritis and Sjgrens syndrome. Anti-ribonuclear P (anti-P) antibodies have been associated with neurolupus, in particular psychosis and severe depression. However, more rigorous meta-analysis casts serious doubt on their value.12 Anti-sn ribonucleoprotein (sn-RNP) antibodies are linked with disease activity, in particular with lupus psychosis and various rheumatic processes such as myositis, oesophageal hypomotility, Raynauds phenomenon, arthralgia, arthritis, sclerodactyly, nephritis and pneumonitis. Anti-Sm antibodies attack the Smith antigen, a soluble nuclear component. They are relatively specific and associated with milder renal and CNS disease and flare-up of SLE. Anti-Ro (SSA) and anti-La (SSB) antibodies target ribonucleoprotein particles. Anti-Ro is implicated in photosensitivity, lung disease, lymphopenia and nephritis. Anti-La, on the other hand, is associated with neonatal and late onset SLE, and secondary Sjgrens syndrome. It may offer protection from anti-Ro associated nephritis. Anti-histone antibodies are found in all cases of drug induced SLE. These are directed against several of the protein components of nucleosides. A small minority of those with rheumatoid arthritis, primary biliary cirrhosis and scleroderma carry these antibodies. Antiphospholipid antibodies13 may be of IgG, IgM or IgA isotypes and form part of a spectrum of circulating antibodies. Originally thought to be directed against phospholipids or cardiolipin (hence anticardiolipin antibodies), they are now recognised to attach to a serum protein called 2 glycoprotein 1 (B2GP1) which in turn attaches to cardiolipin in vitro. These antibodies are also involved in the lupus anticoagulant which may coexist or occur even if antiphospholipid antibody/ 2GP1 levels are normal. Antiphospholipid antibodies compete with clotting factors and enhance aspects of the coagulation cascade, with prolongation of the prothrombin time that is not corrected by mixing the sample with normal plasma. This is a paradox as in vitro they cause an anticoagulant effect but in vivo they are associated with arterial and venous thrombosis.
10.1136/jnnp.2009.200071

Joseph, Scolding 7

genes and hormones could all contribute to lupus related processes. Much recent interest has focused on apoptosis (programmed cell death) in SLE. Antibodies to C1q complement protein are common in SLE, and can cause a functional deficiency of C1q and so defective clearance of apoptotic cells leading to an increase in circulating nucleosomes (essentially circulating DNA fragmentation products of apoptosis) and so to antinucleosome antibody production.7 These theories could help explain some of the precipitants of disease activity (for example, sunlight and viral infections) may increase the number of apoptotic cells in the skin and blood with release of intracellular antigens leading to increased autoantibody generation. These diverse mechanisms probably overlap to produce the spectrum of phenotypes typical of SLE.

THe CLiNiCAL MANiFeSTATiONS OF NeUrOLUPUS

The ACR has proposed specific criteria for the diagnosis of neurolupus (table 4).14 Headaches are common, but chronic tension-type headaches are no more frequent than in the general population. The incidence of migraine has been suggested to be higher. However, a recent meta-analysis has been extremely helpful in exploring the relationship between headache and SLE, concluding that the prevalence of all headache types, including migraine, was not different from controls with insufficient evidence for the concept of lupus headache.15 Idiopathic intracranial hypertension has been described in lupus, sometimes as an initial feature, with the typical findings of bilateral papilloedema and raised CSF opening pressure without focal neurological signs. Seizures are a well recognised complication,16 occurring in 1425% of SLE patients compared with 0.51% in the general population. They are usually generalised but partial episodes also occur. Although accompanying systemic and other CNS features are usually present, seizures may be one of the earliest manifestations of neuropsychiatric involvement, sometimes occurring several years prior to generalised SLE, understandably leading to the erroneous diagnosis of an isolated epilepsy. Several mechanisms may cause seizures in SLE but CSF pleocytosis in such cases raises the possibility of a low grade lupus related

Figure 3 Antinuclear antibodies in systemic lupus erythematosus (SLE). Antinuclear antibodies (green, FITC labelled) from patients with SLE attacking human epithelial cells, counterstained with Evans Blue (red).

TABLe 4 Neuropsychiatric manifestations of systemic lupus erythematosus

Central nervous system Aseptic meningitis Cerebrovascular disease Demyelinating syndrome Headache (including migraine and idiopathic intracranial hypertension) Movement disorder (chorea) Myelopathy Seizure disorder Acute confusional state Anxiety disorder Cognitive dysfunction Mood disorder Psychosis Peripheral nervous system Acute inflammatory demyelinating polyradiculopathy (GuillainBarr syndrome) Autonomic disorder Mononeuropathy, single or multiplex Myasthenia gravis Cranial neuropathy Plexopathy Polyneuropathy
www.practical-neurology.com

8 Practical Neurology encephalitis. Furthermore, the common finding of cerebral atrophy in SLE may also predispose to seizures. Stroke and recurrent transient ischaemic attacks occur in 520% of SLE patients, at a mean age of 37 years (range 2650 years), from our own study,17 possibly leading to multiinfarct dementia in some cases. Intracranial venous thrombosis is another complication. There is evidence to support an APA and lupus anticoagulant induced coagulopathy but the alternative possibilities of embolism from LibmanSacks endocarditis or hypertension from nephritis must not be overlooked. The antiphospholipid antibody syndrome is defined as the association of APAs with arterial or venous thrombosis, recurrent fetal loss, thrombocytopenia or neurological disorders, such as stroke, transient ischaemic attacks, transverse myelopathy, chorea, seizures and migrainous headache.18, 19 It was first described in patients with SLE (secondary antiphospholipid syndrome) but it may also occur in the absence of any other disorder (primary antiphospholipid syndrome). A devastating malignant form with multiorgan involvement including the CNS, catastrophic antiphospholipid syndrome, is well recognised.20 A detailed discussion of this group of disorders closely related to neurolupus is beyond the scope of this brief review. Psychiatric and cognitive disturbances 21, 22 occur in 3075% of SLE patients, the wide range reflecting large variation in diagnostic criteria for such disorders. There is no single characteristic clinical picture although three relatively distinct syndromes are recognised. Pure behavioural or psychiatric illness without clouding of consciousness. Subacute encephalopathy/encephalitis. Dementia. In the first category, affective disorders such as depression and anxiety are particularly common, and while there is evidence that these could be a direct manifestation of SLE, they may be a secondary response to a life altering chronic illness. A lupus psychosis is also described23 (although one should be careful to differentiate it from iatrogenic steroid induced psychosis). Delusions, visual and auditory hallucinations, catatonia and conversion disorders are all recognised.
10.1136/jnnp.2009.200071

Cognitive impairment24 (particularly objective memory testing abnormalities and deficits in attention and visuospatial function) are frequent. Interestingly, impairment of neurocognitive function may be observed in patients, even when their illness is apparently quiescent. Various case series of neurolupus in older people have emphasised subacute confusional state, dementia and depression, and suggested that neurolupus may be more common in this age group than previously assumed.17 Underlying mechanisms such as temporary autoantibody effects or the indirect effects of depression mean that cognitive dysfunction in SLE is potentially reversible although this does not apply to multi-infarct dementia. Aseptic meningitisacute, chronic or recurrentis rare although pathology studies demonstrate meningeal inflammation in almost one-fifth of cases. It is seldom an initial feature of SLE but tends to occur early in the course of the disease and may herald further CNS problems such as transverse myelitis and strokes. SLE should therefore be included in the differential diagnosis of recurrent aseptic meningitis. Aseptic meningitis in SLE can also be associated with non-steroidal anti-inflammatory drugs. Fortunately, withdrawal of the offending drug and steroid therapy invariably lead to recovery. Movement disorders such as chorea are often regarded as a classical neurological complication of SLE but in fact occur in less than 4% of SLE patients. They are more likely to appear during an acute flare of the disease, particularly in women under the age of 30 years who tend to develop generalised or hemichorea. This is usually subtle and transient but may be more prolonged, recurrent or permanent in some. Chorea of SLE is an important differential diagnosis of rheumatic fever in children. Hemiballismus due to infarction of the subthalamic nucleus, ataxia due to cerebellar and brainstem involvement, myoclonus, torticollis and blepharospasm have all been documented. Tremor is recognised in SLE but parkinsonism is rare; the few case reports in patients of varying ages have generally had severe CNS involvement with little or no response to antiparkinsonian medication but good improvement with steroids and immunosuppressants.

Joseph, Scolding 9

Myelopathy is one of the most disabling complications of SLE but fortunately is unusual,25, 26 with a prevalence of 15% of SLE patients. Despite this infrequency, it has a tendency for early involvement: in 39% of neurolupus cases with myelopathy, the spinal disorder occurs as the initial presentation of SLE, while in a further 42% spinal involvement occurs within the first 5 years of SLE diagnosis. Lupus myelopathy is usually acute or subacute, with a raised CSF protein and lymphocyte count (rarely the CSF is normal). MRI with gadolinium enhancement shows changes in the affected region of the cord, often extensive in length in the cervical to mid-thoracic region, usually with cord swelling. Interestingly, a link with antiaquaporin antibodies and neuromyelitis optica (NMO) has emerged recently.27 Cranial neuropathy is relatively uncommon and often transient. An autoimmune optic neuropathy is well described, and again there is an emerging link with NMO and its associated autoantibody.27 Trigeminal sensory neuropathy or typical trigeminal neuralgia may occur as an isolated neurological manifestation in SLE or as part of a mononeuritis multiplex. Demyelination in SLE? On the relationship between demyelinating disease and neurolupus, the pendulum has swung most engagingly over the past few decades. In 1972, Fulford et al coined the term lupoid sclerosis to describe clinical similarities, and a possible underlying aetiopathogenetic link, between SLE and demyelinating syndromes.28 Optic neuritis, brainstem and cerebellar syndromes, subacute myelopathy and other transient neurological deficits in the context of SLE may all mimic multiple sclerosis clinically and radiologically. However, pathological studies of individuals with CNS lupus confirmed that this is a distinct disorder, with no evidence of primary demyelination9; the consensus became that the phenotypic similarities did not reflect common mechanisms.7 More recently still, however, the occurrence of optico-spinal syndromes clinically resembling NMO, combined with the important observation of seropositivity for NMO antibodies, has re-emphasised the possibility of a shared immunological basis for some neurolupus phenotypes and the NMO subtype of demyelinating disease.27

Other ocular structures are commonly involved in SLE, requiring careful ophthalmological evaluation. Furthermore, the clinician needs to assess whether the eye condition is caused directly by SLE, a complication of SLE, or by toxicity of therapy. Retinopathy is frequently observed with cotton wool exudates (indicative of local retinal ischaemia) and haemorrhages, and less frequently, perivascular sheathing and fibrosis. Abnormal eye movements and ptosis (often unilateral) are occasionally reported as a recurrent feature in a number of patients. Proposed mechanisms include focal or widespread brainstem disease, or cranial nerve vasculitis. Choroidopathy is probably more common than generally appreciated and is often an indicator of severe underlying systemic disease but uveitis is uncommon. Peripheral nervous system involvement.29 Although less common than CNS involvement, peripheral neurological complications do occur in SLE: Mononeuritis multiplex. Acute inflammatory demyelinating polyneuropathy (GuillainBarr syndrome). Chronic inflammatory polyneuropathy.30 There is a suggested association with myasthenia gravis31 (which should be particularly considered as a differential diagnosis of some of the possible ocular manifestations described above), the LambertEaton syndrome and following thymectomy.

Secondary factors
While not considered in detail here, neuropsychiatric complications resulting from factors other than the primary disease process should not be neglected in practice. Intercurrent infections and immunosuppression by drug therapy may be major causes of morbidity and mortality, making it essential to exclude conventional and opportunistic organisms.32 Other adverse effects of drugs are common; steroid therapy in particular can cause psychosis and hypertension. Chronic renal failure may increase blood pressure and lead to metabolic derangements with further potential for adverse neuropsychiatric effects.
www.practical-neurology.com

10 Practical Neurology

risk factors for CNS involvement and outcome in SLe

There appear to be several risk factors for CNS involvement and a poor prognosis.33 Individuals with prior neuropsychiatric involvement are at greater risk than other SLE patients of developing (further) neurological complications. There is also an increased risk with the antiphospholipid syndrome as well as its features (in particular, arterial thrombosis and cutaneous vasculitic lesions), and with thrombocytopenia, positive antinuclear antibodies (ANA), anti-SS-B/La and low serum levels of C3 and C4 complement components. Patients with this profile may require closer observation and are potential candidates for studying pre-emptive interventions. Somebut not allauthors believe that articular involvement and discoid rash may be protective against the development of neurolupus features.

the presence of any of the neuropsychiatric features, as outlined in the ACR list (table 4). Such features may be very early or even the first presentation of SLE, posing a significant diagnostic challenge.17 Recommended investigations for neurolupus are listed in table 5.

Blood tests and serology

There is no specific diagnostic blood test for neurolupus, but in conjunction with relevant clinical features of the disease itself, various blood tests are nonetheless helpful. Routine biochemistry may detect associated renal impairment or electrolyte disturbances, either from SLE or iatrogenic drugs. A full blood count may show anaemia, leucopenia or thrombocytopenia. The erythrocyte sedimentation rate is a sensitive but non-specific indicator of disease activity in SLE; C reactive protein (CRP) has a shorter half-life and rapidly reflects acute inflammation. Classically (but not reliably) in active SLE, the erythrocyte sedimentation rate is raised and the CRP is low. Therefore, a very high CRP may distinguish between bacterial infection and active SLE. Low C3 and C4 levels may be helpful but SLE can be active without causing any of the above changes. More diagnostically discerning is the assay of autoantibodies (table 3). These are usually polyclonal and often directed against multiple targets. As the name implies, ANA are antibodies directed against nuclear components. Although persistent ANA negative SLE is recognised,34 it is not clear if this truly represents a subgroup of SLE or a technical artefact. No specific titre of ANA is defined as abnormal by the ACR, but in general, high titres (>1/160, but preferably >1/300 depending on the laboratory and test used) in young patients are diagnostically meaningful. One needs to consider these results in their clinical context, as positive ANA are also encountered in those who are unwell or older and even in some normal individuals.35 Further specific tests looking for anti-DNA antibodies and extractable nuclear antibodies are more defining of SLE. Anti-DNA antibodies are a reasonably specific diagnostic test but are positive in only about 70% of SLE patients, rising in active diseasethey can be negative

MAKiNG THe DiAGNOSiS OF NeUrOLUPUS

The many clinical manifestations of SLE can make the diagnosis difficultafter all, there are 120 different combinations of four out of 11 features of the ACR diagnostic criteria (table 1). Furthermore, these are permitted at some time in the course of the illness and one should therefore not exclude the possibility of SLE, even if the criteria are not satisfied at the outset. The next stage involves confirming

TABLe 5 recommended investigations for neurolupus

Full blood count Urea, electrolytes, creatinine, glucose Liver function tests Urinalysis Complement levels: C3/C4 ANA, anti-DNA, anti-ENA antibodies Antiphospholipid antibody, lupus anticoagulant, thrombophilia screen, cryoglobulins CSF: cells, protein, glucose, oligoclonal bands, culture MRI brain and/or spine with gadolinium EEG Other tests when indicated: CT brain, echocardiogram, MR angiography, catheter angiography, SPECT, PET ANA, antinuclear antibodies; ENA, extractable nuclear antibodies; PET, positron emission tomography; SPECT, single photon emission computed tomography.
10.1136/jnnp.2009.200071

Joseph, Scolding 11

early in disease, following treatment, or in clinical remission, and are also sometimes found in normal individuals, in Sjgrens syndrome and in those with rheumatoid arthritis (see also table 3). APAs are seen in 1660% of those with SLE. Although not all patients with these antibodies have the APA syndrome, IgG antibodies and 2 glycoprotein 1 in particular are recognised risk factors for thrombosis. Additional lupus anticoagulant testing is essential because this finding also predisposes to thrombosis and may occur in the absence of APAs. Although it would be unusual for all of these antibodies to be absent in a case of neurolupus, their temporary absence does not (sadly) exclude the diagnosis.

Spinal fluid examination

There are mild and non-specific abnormalities in 3090% of patients with neurolupus; a modestly raised white cell count (predominantly mononuclear) and protein. The CSF glucose is usually normal but can occasionally be depressed, especially in SLE related myelopathy. Oligoclonal bands are reported in 1580% of cases (both matched and unmatched with serum); these appear to be promoted by specific cytokines in the CSF such as interleukins 6, 8 and 10, which are increased almost 10-fold in the CSF of those with neurolupus compared with nonCNS lupus. Furthermore, reduced interleukin 6 CSF activity after remission of CNS symptoms with cytotoxic therapy is recognised while resistance to treatment is associated with persistent elevation.

Figure 4 MRI in systemic lupus erythematosus. Axial fluid attenuated inversion recovery (FLAIR) images showing multiple small lesions of high signal intensity in the white matter. There is no evidence of atrophy. Reprinted with permission from Graham JW, Jan W. MRI and the brain in systemic lupus erythematosus. Lupus 2003;12:8916.

Structural imaging
Although CT brain imaging is not the most sensitive marker of neurolupus, it readily detects and differentiates between infarcts and haemorrhages, with generally good correlation with stroke-like presentations. One consistent finding in chronic cases is cortical atrophy (usually perisulcal), which may be a direct result of local lupus related disease processes or secondary to microinfarcts or long term steroid therapy. MRI is far better at revealing small infarcts, focal cerebral oedema and (of course) myelitis. Unsurprisingly, the pattern of clinical involvement is reflected in the MRI features: localised neurological signs and seizures are

associated with focal MRI abnormalities more frequently than a diffuse presentation with an organic brain syndrome, psychosis, headache and/or meningism. There is however no one MRI finding or pattern that is diagnostic or specific for neurolupus.36, 37 Nonetheless, some characteristic changes have been proposed: acute lesions typically lack discreet borders, are intermediate intensity on T2 weighted images, have a lacy/filamentous pattern, are semilunate in shape and are located at the greywhite matter junction along sulci and gyri, or in the white matter with overlying grey matter hyperintensity. These lesions tend to enhance with gadolinium, so contrast studies are recommended within 24 h of the neurological event. These high intensity lesions may potentially resolve with steroids. In addition, MR sequences with fluid attenuated inversion recovery and diffusion weighted imaging enhance the sensitivity and specificity for the diagnosis, but only partially (figure 4). Clinicalradiological correlates are not always obvious. MRI lesions may represent a prior attack of neurolupus or may resolve completely within days in parallel with clinical improvement. To complicate the situation further, a significant proportion of SLE patients with neither active nor historically identifiable neurolupus have MRI abnormalities which increase with age and with the presence of vascular risk factors. These chronic lesions tend to be small, punctate, focal white matter changes that rarely enhance with gadolinium. They are
www.practical-neurology.com

12 Practical Neurology is a good illustration of the value of functional imaging18F deoxyglucose PET in other choreic disorders reveals characteristic glucose hypometabolism in the striatum which is not reproduced in SLE patients with chorea, supporting the possibility that chorea results from the effects of cytotoxic antibody (possibly APA) on the basal ganglia.40

PrACTiCe POiNTS
In practice, serious neurological lupus is not common. Peripheral nervous system involvement is significantly less common than CNS lupus. Targeted investigations, properly interpreted, are often diagnostic, while imaging is generally more important in excluding alternative diagnoses than confirming neurolupus. Both lupoid sclerosis and lupus vasculitis are (usually) misleading terms. There is very little evidence on which to base treatment recommendations; but in thrombotic disease, previous advice that warfarin is superior to aspirin, and that high dose warfarin is better than low, are both now seriously questioned. Cyclophosphamide and steroids should probably be used in inflammatory disease.

electroencephalography
EEG is regarded as a very sensitive though non-specific investigation in cerebral lupus, with abnormalities in even the most subtle or diverse of neuropsychiatric manifestations. Although any changes are often diffuse, some researchers have specified more focal abnormalities with selective involvement of the left temporal or temporolimbic regions.

indistinguishable from age related small vessel disease changes but are probably more common than in non-SLE, although there are no population based comparative studies. Volumetric magnetisation transfer imaging is more sensitive to structural brain damage than conventional MRI. It has proven to be particularly valuable in distinguishing between active neurolupus and residual disease, which may in turn help in establishing who to treat. It may also be useful for treatment trials and for studying the natural history of the disease.

Histopathology
The important pathological features have been described above. The character of cerebral involvement in SLE and the perceived risks of biopsy in these circumstances, however, often mean that tissue diagnosis is made only at autopsy, if at all; in practice, the greater role of biopsy is arguably in the exclusion of other disorders. Peripheral nerve biopsy is easier and safer, and so may have a useful role in investigating neuropathy in SLE.

Functional brain imaging

Altered cerebral blood flow (CBF) in neurolupus patients has been detected by radionuclide brain scans, positron emission tomography (PET) and single photon emission computed tomography (SPECT). Both a decrease in mean CBF and an abnormal CBF regional distribution have been observed in diffuse as well as focal CNS presentations. These often normalise after resolution of the CNS symptoms and sometimes after treatment. PET and SPECT are sensitive although non-specific diagnostic imaging tools. They are finding a niche in helping to detect subclinical CNS involvement in SLE, in revealing irregularities in patients with cerebral involvement but normal MR scans and in helping to explore underlying pathological mechanisms (eg, the role of hypoperfusion) in certain SLE manifestations.38, 39 CT and MRI of patients with chorea in SLE (a putative antibody mediated neurological manifestation) are usually normal; here there
10.1136/jnnp.2009.200071

THe TreATMeNT OF NeUrOLUPUS

Although neurolupus is often serious and sometimes fatal, it is potentially treatable. Unfortunately, there is an extraordinary lack of large randomised trials and so retrospective studies and observations provide the main evidence. Notwithstanding the array of neurological disorders in SLE and their multifactorial aetiology, therapeutic efforts largely fall into three categoriesstroke prevention, immunosuppression and symptomatic treatment (the last we will not discuss).

Stroke prevention
There is evidence that APAs, 2GP1 and the lupus anticoagulant are significant independent risk factors for stroke, and most authors do not doubt the use of antithrombotic therapy in patients with these antibodies and thromboembolic events. However, the evidence base for therapy is by no means perfect. Various guidelines commonly propose that warfarin is

Joseph, Scolding 13

superior to aspirin, and high dose warfarin best of all, but recent trials and systematic reviews suggest otherwise. While further studies are required, an emerging consensus suggests that warfarin at doses aiming for a higher international normalised ratio range than usual confers significantly greater risks but no benefits in patients with APAs41; and in fact, warfarin does not appear to be superior to aspirin in the prevention of arterial thromboembolic complications in patients with a first ischaemic stroke and APAs.4143 It should be stressed that this evidence largely comes from studies with primary antiphospholipid syndrome; recommendations for patients with APAs in the context of SLE are far less clear-cut. Even less consensus has emerged for primary prevention although aspirin is commonly recommended.

Corticosteroids and immunosuppressants

We are aware of only a single randomised trial assessing steroids and/or immunosuppression in neurolupus, and this included only 32 patients.44, 45 It suggested that for serious (non-stroke) neurological complicationsincluding seizures, optic neuritis, neuropathy, coma, brainstem disease or transverse myelitissteroids alone were inferior to steroids plus cyclophosphamide. There have, however, been many studies in lupus nephritis which clearly reach the same conclusion, and in the absence of a better evidence base, a common recommendation is therefore to start with high dose intravenous methylprednisolone, 1 g daily for 3 days (followed by oral prednisolone 60 mg/day, decreasing by 10 mg at weekly intervals to 10 mg/day if possible) accompanied by oral or intravenous cyclophosphamide. Oral administration is easier2.5 mg/kg/day (lower dose of 2 mg/kg in the older people or in renal failure) for perhaps 912 weeks (pulsed weekly intravenous cyclophosphamide appears to differ insignificantly in efficacy from daily oral treatment and it may have fewer adverse effects). Careful monitoring of the blood count for bone marrow suppression should force a reduction in dose if there is leucopenia (total white cell count <4.0109) or neutropenia (<2.0109). Cyclophosphamide is associated with haemorrhagic cystitis (a complication reduced by adequate hydration and MESNA cover), a 33-fold increase in bladder cancer, other malignancies, infertility, cardiotoxicity and pulmonary fibrosis.

Conversion at around 3 months to a maintenance regimen of alternate day steroids (1020 mg prednisolone) and substituting azathioprine (2 mg/kg/day) for methotrexate (starting dosage 7.5 mg/week, increasing or decreasing 2.5 mg/week according to response or adverse effects; maximum 20 mg/week) for cyclophosphamide can be instituted for a further minimum of 10 months, depending on response, followed by gradual withdrawal.46 Mycophenolate and ciclosporin may be as effective as methotrexate and azathioprine.47 Case reports and small series suggest intravenous immunoglobulin may be of value, and thalidomide also appears to have helped some patients. Biological agentsprincipally monoclonal antibodiesdesigned to interfere with T cell activation, T cellB cell collaboration or to inhibit production or deposition of anti-dsDNA antibodies and complement, or cytokine activation, are all under active consideration.48, 49

ACKNOwLeDGeMeNTS
This article was reviewed by Richard Davenport, Edinburgh, UK.
Competing interests: None Provenance: Commissioned; externally peer reviewed.

reFereNCeS
1. 2. Jimnez S, Cervera R, Font J, et al. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 2003;25:312. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. Hanly JG, McCurdy G, Fougere L, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004;31:215662. Hanly JG, Fisk JD, McCurdy G, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2005;32:14596. Hanly JG, Su L, Farewell V, et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 2009;36:144959. Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001;57:496500. Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol 2002;28:17389. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 1968;47:33769.

3.

4.

5.

6.

7.

8.

www.practical-neurology.com

14 Practical Neurology
9. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 19551977. Semin Arthritis Rheum 1979;8:21221. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988;23:3804. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992;19:73241. Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006;54:31224. Asherson RA, Cervera R, Merrill JT, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost 2008;34:25666. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599608. Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004;127:12009. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006;15:1917. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology 2007;69:64454. Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol 2009;83:116. Wong RC, Favaloro EJ. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost 2008;34:295304. Bayraktar UD, Erkan D, Bucciarelli S, et al; Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 2007;34:34652. Scolding NJ, ed. Systemic inflammatory diseases and the nervous system. In: Contemporary treatments in neurology. Oxford: Butterworth Heinemann, 2001:187215. Stojanovich L, Zandman-Goddard G, Pavlovich S, et al. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 2007;6:4216. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 2008;47:1498502. Denburg SD, Carbotte RM, Denburg JA. Cognition and mood in systemic lupus erythematosus. Evaluation and pathogenesis. Ann N Y Acad Sci 1997;823:4459. Kovacs B, Lafferty TL, Brent LH, et al. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000;59:1204. 26. Espinosa G, Mendizbal A, Mnguez S, et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 2008. Epub ahead of print. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:7883. Fulford KW, Catterall RD, Delhanty JJ, et al. A collagen disorder of the nervous system presenting as multiple sclerosis. Brain 1972;95:37386. Rosenbaum R. Neuromuscular complications of connective tissue diseases. Muscle Nerve 2001;24:15469. Vina ER, Fang AJ, Wallace DJ, et al. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum 2005;35:17584. Bhinder S, Majithia V, Harisdangkul V. Myasthenia gravis and systemic lupus erythematosus: truly associated or coincidentaltwo case reports and review of the literature. Clin Rheumatol 2006;25:5556. Cuchacovich R, Gedalia A. Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am 2009;35:7593. Karassa FB, Ioannidis JP, Touloumi G, et al. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM 2000;93:16974. Creamer P, Kirwan J. Seronegative systemic lupus erythematosus. Br J Rheumatol 1992;31:61922. Craig WY, Ledue TB, Johnson AM, et al. The distribution of antinuclear antibody titers in normal children and adults. J Rheumatol 1999;26:91419. Appenzeller S, Pike GB, Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol 2008;34:3616. Graham JW, Jan W. MRI and the brain in systemic lupus erythematosus. Lupus 2003;12:8916. Peterson PL, Axford JS, Isenberg D. Imaging in CNS lupus. Best Pract Res Clin Rheumatol 2005;19:72739. Castellino G, Govoni M, Giacuzzo S, et al. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev 2008;7:297304. Guttman M, Lang AE, Garnett ES, et al. Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea. Mov Disord 1987;2:20110. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:11338. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of highintensity warfarin vs. conventional antithrombotic therapy for the prevention

10.

27.

28.

11.

12.

29.

30.

13.

31.

14.

32.

15.

33.

16.

34.

17.

35.

18.

19.

36.

20.

37.

38.

21.

39.

22.

40.

23.

41.

24.

25.

42.

10.1136/jnnp.2009.200071

Joseph, Scolding 15
of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:84853. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:10507. Trevisani VF, Castro AA, Neves Neto JF, et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2006;19:CD002265. Barile-Fabris L, Ariza-Andraca R, Olgun-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005;64:6205. Fortin PR, Abrahamowicz M, Ferland D, et al; Canadian Network For Improved Outcomes in Systemic Lupus. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008;59:1796804. Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007;2:96875. Garca-Carrasco M, Jimnez-Hernndez M, Escrcega RO, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009;8:3438. Robak E, Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets 2009;10:2637. Lie JT. Classification and histopathologic spectrum of central nervous system vasculitis. Neurol Clin 1997;15:80519.

43.

47.

44.

48.

45.

49.

50.

46.

www.practical-neurology.com